Patent · US Active

Compositions and methods for inhibiting expression of Nav1.8 gene

US7902168B2 · kind B2 · utility

1Cited by

0References

11Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Dinah Wen-Yee Sah · Boston, US
Maria Frank-Kamenetsky · Brookline, US
Anke Geick · Bayreuth, DE
Philipp Hadwiger · Kulmbach, DE
Ingo Roehl · Memmelsdorf, DE
Pamela Tan · Kulmbach, DE
Hans-Peter Vornlocher · Bayreuth, DE

Key dates

Filing date	Jun 18, 2009
Grant date	Mar 8, 2011
Priority date	—
Expiry date	Jun 18, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.